The Motley Fool··Jake LerchBoxer Capital Doubles Down on TNGX With $9.5M Stake as Biotech Stock Soars
Boxer Capital invests $9.5M in clinical-stage biotech $TNGX, raising stake to 21.09%, as stock surges 427% amid Gilead partnership momentum.
GILDTNGXIBBbiotechclinical-stage